Interleukin 17A: toward a new understanding of psoriasis pathogenesis.
about
Th17 cells in autoimmune and infectious diseasesA systematic review and meta-analysis on Staphylococcus aureus carriage in psoriasis, acne and rosaceaNew and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitorsIL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A TherapiesKLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton SyndromeInterleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseasesTreatment challenges in the management of moderate-to-severe plaque psoriasis - role of secukinumabSecukinumab for ankylosing spondylitis and psoriatic arthritisFirst-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasisMast cell-mediated and associated disorders in pregnancy: a risky game with an uncertain outcome?Hyperreactive onchocerciasis is characterized by a combination of Th17-Th2 immune responses and reduced regulatory T cells.Proteogenomic analysis of psoriasis reveals discordant and concordant changes in mRNA and protein abundance.Protective effects of SIRT1 in patients with proliferative diabetic retinopathy via the inhibition of IL-17 expressionCalcitonin Gene-Related Peptide-Exposed Endothelial Cells Bias Antigen Presentation to CD4+ T Cells toward a Th17 Response.Therapeutic Effects of Erythroid Differentiation Regulator 1 on Imiquimod-Induced Psoriasis-Like Skin Inflammation.Influence of different types of contact hypersensitivity on imiquimod-induced psoriasis-like inflammation in miceInterleukin-21 is associated with the severity of psoriasis vulgaris through promoting CD4+ T cells to differentiate into Th17 cellsNeutrophil extracellular trap formation is increased in psoriasis and induces human β-defensin-2 production in epidermal keratinocytes.Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies.Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study.Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy.Secukinumab: a review in moderate to severe plaque psoriasis.Novel systemic therapies for the treatment of psoriasis.The critical role of macrophages in the pathogenesis of hidradenitis suppurativa.The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis.Emerging drugs for psoriatic arthritis.Psoriatic arthritis and psoriasis: differential diagnosis.Current challenges and emerging drug delivery strategies for the treatment of psoriasis.The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.Reducing Flightless I expression decreases severity of psoriasis in an imiquimod-induced murine model of psoriasiform dermatitis.Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).Tofacitinib for the treatment of psoriasis.Brodalumab for the treatment of psoriasis.Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment.Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy.IL-17A plays a central role in the expression of psoriasis signature genes through the induction of IκB-ζ in keratinocytes.Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study.Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa.Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis.The Clinical Significance of Increased Serum Proinflammatory Cytokines, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Patients with Hidradenitis Suppurativa.
P2860
Q21284677-B341F1CB-C7B4-4827-8C99-9B9D10F85AA3Q26752267-E63AC4C0-2CDA-4612-8502-ED7F31383903Q26800937-304CCAFC-B514-4B01-A437-085A8DB7EFA0Q26830943-AB73A86B-6C50-484F-BC7F-E5832B3032B4Q27310680-4DBEF5C6-6913-40FB-87BE-01934E511C0EQ28069350-B6434BF8-05DA-408F-AA2B-9963F75BB906Q28069819-E32D7AD5-0879-45C7-9CB8-667E2C6A4280Q28071474-EEC49871-D3B3-4A11-A56E-5EE2C5E0ACA1Q33593625-DB57E7C5-A3D7-429E-BAD2-239C4C7FD085Q33658543-FE21AD07-6D51-4276-B3FD-CB31991B9895Q34888523-8AB48832-22C6-4D9A-9F5C-FABF5A543B8BQ35922976-0D859256-133F-4DF6-9EB7-EBFE7E5BE63DQ36502289-E5337797-8DD7-4B8D-B290-472A844DF26EQ36601088-0F904312-6058-4820-9BAF-C82898AE4873Q36667189-2BCE4470-3B71-45BE-AAF7-26A6E3DAD63CQ37032431-A41F338C-E3EA-4CE4-AEAA-BE60013D066FQ37144124-733B815D-F1DC-4CBC-B821-95C94A25304DQ37153882-0B428C68-2941-4447-9020-9D8394009DD9Q37432244-4F62A0C8-2A15-4F69-807D-4042FAFF9D85Q37631138-0D893CFA-2172-429F-AB4E-C3BC87254004Q38273695-8AF2C007-6EA5-4B72-9316-9A17A0621D8BQ38552526-EC136845-F19D-4CF7-8252-7164E03661B6Q38628193-755E4EAF-EF6D-4E03-BC47-2A6EB1CB5A71Q38665824-B755C7E7-0C12-4149-AE78-BC2F49CFB087Q38707588-6DBD92B0-E788-4D35-AC29-4D832305CB79Q38710642-15A3C9F4-676D-44FA-B487-3AE75CEE55E3Q38828427-F138E9C3-B4E3-49A4-96B6-08F7F93B1959Q38831055-82C4F49C-A309-4C39-BBB2-8ECB3BBE60DCQ38840275-79E52FF0-B672-42FB-9085-ABC4FD666628Q38845758-382CFE43-19C0-473A-AB45-347B60EEC10BQ38856226-B2966BD2-A41B-4768-916B-7D4B59449A88Q38856883-82A30746-D99A-4FBF-ADDB-940FA23839E0Q38975719-7EADFB27-3A62-4927-B5AB-BD564F20BF0FQ39165518-B9A19B9A-82CE-4CA3-B942-F0B362ACD3A7Q39458219-5AC2A9BF-165F-4F8B-90EC-689674703D3FQ39947458-56719739-B51A-46A1-BC57-35396B3DA796Q40217411-F821A15E-AC0A-477F-A79F-00ABB0A666BDQ40966336-A85FD6F1-C114-4DC9-AACB-B58E04A75290Q41039794-7BE8BC76-7A82-4635-8E20-B4C42CCA9E6CQ41100402-F2E23088-D3BD-4200-8A4A-94693F2E5A9C
P2860
Interleukin 17A: toward a new understanding of psoriasis pathogenesis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Interleukin 17A: toward a new understanding of psoriasis pathogenesis.
@en
type
label
Interleukin 17A: toward a new understanding of psoriasis pathogenesis.
@en
prefLabel
Interleukin 17A: toward a new understanding of psoriasis pathogenesis.
@en
P2093
P1476
Interleukin 17A: toward a new understanding of psoriasis pathogenesis.
@en
P2093
Charles W Lynde
Marc Bourcier
Sam Khalil
Yves Poulin
P304
P356
10.1016/J.JAAD.2013.12.036
P407
P577
2014-03-18T00:00:00Z